| |
Software Requirements
Microsoft Internet Explorer 5.01 or higher and Netscape Navigator 4.75 or higher are recommended. |
|
 |
J.Health Sci., 55(5), 750-756, 2009
An Environmental and Biological Study of Occupational Exposure to Cyclophosphamide in the Pharmacy of a Japanese Community Hospital Designated for the Treatment of Cancer
Manabu Tanimura,*, a, b Kiyofumi Yamada,b
Shin-ichi Sugiura,c Keiki Mori,a
Hiroaki Nagata,a Kyoko Tadokoro,a
Tomohiro Miyake,a Youko Hamaguchi,a
Paul Sessink,d and Toshitaka Nabeshimae, f
aDepartment of Pharmacy, Yamada Red Cross Hospital, 810 Takabuku Misono-cho Ise 516-0805, Mie, Japan,
bDepartment of Neuropsychopharmacology & Hospital Pharmacy, Graduate School of Medicine, Nagoya University, 65 Turuma-cho, Showa-ku, Nagoya 466-8560, Japan,
cDepartment of Medical Systemology, Graduate School of Medicine, Nagoya University, 65 Turuma-cho, Showa-ku, Nagoya 466-8560, Japan,
dExposure control B. V., P.O. Box 467, 6600 AL Wijchen, Netherlands,
eDepartment of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya 468-8503, Japan and
fNPO Japanese Drug Organization of Appropriate Use and Research, Japan, 150 Yagotoyama, Tenpaku-ku, Nagoya 468-8503, Japan
Cancer treatment in Japan is considered to be very progressive in the use of antineoplastic agents. Pharmacists are required to compound more antineoplastic preparations recently and thus are at risk for exposure to antineoplastic agents. In Japan, healthcare professionals have recognized the need for protection, but there have been few reports of environmental contamination or occupational exposure to antineoplastic agents. In the present study, urine samples over 24 hr from compounding pharmacists and wipe samples from the compounding room were collected to analyze levels of cyclophosphamide (CP). CP was detected in urine samples from all 4 pharmacists (mean=165.3 ng/24 hr) and for all wipe samples of the compounding room. From the results of these tests, the standard operating procedure (SOP) of the pharmacy was revised as a protective measure. The tests were then repeated and CP was detected again in the urine of all 4 compounding pharmacists, though the mean CP level was reduced from 165.3 to 47.4 ng/24 hr after the revision of the SOP. Although there was no correlation between the amount of CP compounded and the CP levels in urine initially, the 2 values were significantly correlated after the revision of the SOP (R2=0.87).
|
|
